Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eton Pharmaceuticals, Inc. (NASDAQ: ETON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eton’s Form 8-K filings in 2025 cover topics such as quarterly financial results, changes in independent registered public accounting firms, index inclusion, product acquisitions, and key regulatory milestones for its rare disease portfolio.
For example, a November 6, 2025 Form 8-K furnishes a press release announcing financial results for the quarter ended September 30, 2025 and explains the company’s use of non-GAAP measures like Adjusted EBITDA. Other 8-K filings describe the FDA’s acceptance of the New Drug Application for ET-600, a proprietary desmopressin oral solution, and Eton’s addition to the Russell 2000 and Russell 3000 indexes. An 8-K/A filed on November 18, 2025 provides historical financial statements and unaudited pro forma condensed combined financial information related to the acquisition of INCRELEX.
Through these filings, investors can review Eton’s reported net revenues, product sales trends, research and development spending on programs such as ET-600, ET-700, and ET-800, and general and administrative expenses associated with commercial launches. Filings also document governance and audit matters, including the June 20, 2025 8-K reporting the dismissal of Crowe LLP and the appointment of Grant Thornton LLP as the new independent auditor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the main points of complex documents, such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly understand what each filing means for Eton’s rare disease strategy, financial position, and regulatory progress, and can also monitor insider and other ownership-related filings like Forms 3, 4, and 5 when available.
Eton Pharmaceuticals has acquired U.S. commercialization rights to HEMANGEOL, an Orphan Drug for infantile hemangioma, through a licensing deal with Pierre Fabre Medicament Sas. Eton will pay
The company will buy about
According to IQVIA data, HEMANGEOL generated
Eton Pharmaceuticals reported that the U.S. FDA has approved its New Drug Application for DESMODA (desmopressin acetate) Oral Solution to manage central diabetes insipidus, or arginine vasopressin deficiency, in patients of all ages. DESMODA is described as the first and only FDA‑approved oral liquid formulation of desmopressin, designed for precise, individualized dosing in a condition where careful titration is critical to maintaining water balance.
The product is supplied as a ready‑to‑use 0.05 mg/mL solution that avoids tablet splitting, crushing, refrigeration, mixing, or shaking. Eton estimates more than 13,000 U.S. patients have central diabetes insipidus, including 3,000–4,000 pediatric patients, and expects DESMODA peak annual sales of $30–50 million. DESMODA will be promoted by Eton’s existing pediatric endocrinology rare disease team and is expected to be available on March 9 exclusively through specialty pharmacy Anovo, which will run the Eton Cares support program with services such as prescription fulfillment, insurance investigation, education, and financial assistance.
Eton Pharmaceuticals director Norbert G. Riedel reported exercising stock options and acquiring additional common shares. On 02/03/2026, he exercised an employee stock option for 30,000 shares of common stock at $4.42 per share.
Following this transaction, he directly held 35,000 shares of Eton Pharmaceuticals common stock. He also had indirect beneficial ownership of 157,145 shares held in the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as a trustee.
Eton Pharmaceuticals reported that it has licensed U.S. marketing rights to an ultra-rare disease product candidate. The product, once approved, is expected to be the first and only generic alternative to an existing treatment for an ultra-rare condition affecting fewer than 100 patients in the United States.
The licensing arrangement was disclosed through a press release dated February 2, 2026, which is attached as an exhibit to the report.
Eton Pharmaceuticals director Norbert G. Riedel reported new equity compensation grants. On January 12, 2026, he was granted options to purchase 12,196 shares of common stock at an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are scheduled to be fully vested and exercisable by January 12, 2027.
On the same date, he also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in four equal annual installments beginning January 12, 2027, contingent on his continued service with the company on each vesting date. Following these grants, he beneficially owns 294,253 derivative securities directly.
Eton Pharmaceuticals director Adams Jennifer McKie reported new equity awards. On January 12, 2026, she received an employee stock option grant for 12,196 shares with an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are expected to be fully vested and exercisable by January 12, 2027.
She also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in one annual installment beginning January 12, 2027, contingent on her continued service with the company on the vesting date(s). Following these grants, she beneficially owns 170,329 derivative securities related to stock options and 178,086 derivative securities related to RSUs, all held directly.
Eton Pharmaceuticals director Charles J. Casamento reported new equity awards. On January 12, 2026, he received an employee stock option covering 12,196 shares of Eton common stock with an exercise price of $15.47 per share. According to the filing, these option shares vest quarterly over 12 months from the grant date and become fully vested and exercisable on January 12, 2027.
On the same date, he was also granted 7,757 restricted stock units. Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in a single annual installment beginning January 12, 2027, conditioned on his continued employment with the company on the vesting date. Following these grants, he beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.
Eton Pharmaceuticals director Paul V. Maier reported new equity awards. On January 12, 2026, he received an employee stock option for 12,196 shares of common stock at a $15.47 exercise price. These options vest quarterly over 12 months from the grant date and are fully exercisable on January 12, 2027.
He also received 7,757 restricted stock units, each representing a contingent right to one share of Eton common stock. These RSUs vest in one annual installment beginning January 12, 2027, contingent on his continued employment with the company. After these derivative awards, the filing shows 286,496 derivative securities following the option grant and 294,253 following the RSU grant, all held directly.
Eton Pharmaceuticals Chief Commercial Officer Erdogan-Trinkaus Ipek reported new equity awards. On January 12, 2026, the executive received an employee stock option for 40,655 shares of common stock at an exercise price of $15.47 per share. These options vest in 48 equal monthly installments from the grant date and become fully vested and exercisable on January 12, 2030.
The filing also shows a grant of 25,856 restricted stock units (RSUs), each representing one share of ETON common stock. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on continued employment on each vesting date. After these grants, the reporting person beneficially owns 123,878 derivative securities tied to options and 149,734 derivative securities tied to RSUs.
Eton Pharmaceuticals President & CEO Sean Brynjelsen, also a director and 10% owner, reported multiple equity transactions. On January 1, 2026, 5,015 shares of common stock were disposed of at a weighted average price of $15.39, with shares withheld by the company to satisfy taxes upon vesting of restricted stock units, leaving him with 2,889,266 common shares held directly.
On January 12, 2026, he was granted an employee stock option for 158,046 shares at an exercise price of $15.47, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring January 11, 2036. He also received 100,517 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment.